Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue.

• DOI: 10.1200/jco.2014.32.15_suppl.e11542
• Publication Date: 2019-01-03T22:23:21Z
• Authors: Ayse Demirci; Necati Alkis; Faysal Dane; Dogan Yazilitas; Ayse Durnali; Mevlude Inanc; Melike Ozcelik; Tulay Akman; Omer Kamil Yazici; Muhammet Ali Kaplan; Arife Ulas; Oznur Bal; Ozlem Sonmez; Saadet Tokluoglu; Yusuf Gunaydin; Gamze Gokoz Dogu; Ozgur Tanriverdi; Umut Demirci; Alper Sevinc; Ibrahim Turker
• Keywords: Invasive lobular carcinoma

e11542 Background: Breast cancer is the most common in women. Approximately 60% of breast are hormone receptor positive. The goal this study to evaluate possible factors affecting survival patients treated with gonadotropin-releasing (GnRH). Methods: Demographic characteristics, treatment modalities, overall and a total 539 premenoposal from 16 different centers Turkey analysed retrospectively. Results: Median age was 36±6.3 (19-53). median tumour size 2.5±1.8 (0.5-13) cm. Estrogen (ER), progesterone (PR), human epidermal growth factor 2 (HER2) positivity rates were 92.0%, 90.4% 31.4% respectively. Histology tumors as follows; invasive ductal carcinoma 85.3%, lobular 4.6%, mixed other subtypes 5.3%. T staging T1, T2, T3, T4 25.8%, 49.9%, 13.4%, 1,7% Lymph node involvement 61.1%. Neoadjuvant therapy, adjuvant chemotherapy radiation therapy applied 8.5%, 88.9% 81.3% patients, duration GnRH analogue use 23.0±13.8 (1-87) months. Patients divided into 3 groups according analogues use. time shorter than 24 months, equal longer months first group (n=268, 49.7%) , second (n=88, 16.3%) third (n=162, 30.1%) follow up 33.5 (1-188). DFS 126.0±11.6 (103-148) According 104.0±31.2 (42.7-165) 116.0±8.4 (99-132) group. But couldn’t be calculated because low recurrence numbers (log rank, p<0,005). There no difference between OS p=0.20). reached only (175.0±66.7 [44-305]). Conclusions: In we can not find optimal premenopausal HR positive patients. Additional prospective randomised studies needed clarify theese results.